This is one of the chapters that's of great concern.
I won't go into the anti-union rhetoric like my colleague, but the concern in this chapter is the extension of patent provisions for drugs. What that means for Canadians is that they will pay more, the cost to the provinces will be higher, and people will be less able to afford medication. I assume that this would impact not just your employees, but you as well.
This is one of the major themes that we hear in push-back around this deal: the cost to Canada. We're already second-highest in the world in drug costs, and any increase to that would seriously cripple our communities and our ability to maintain health in Canada. This is one of the main themes that people oppose.
I have another question. Are you familiar with chapter 9, the investor state dispute settlement chapter?